العلاج من الخط الثاني لسرطان القناة الصفراوية المتقدم أو غير القابل للجراحة (الكولانجيوكارسينوما) مع حالة الأداء الكافية

References

DOI: 10.1136/gutjnl-2023-330029

• CisGem chemotherapy is recommended as the first-line treatment in patients with advanced BTC.
• Combination chemotherapy is recommended in patients with adequate performance status following failure of first-line chemotherapy, particularly in the absence of a targetable molecular alteration.
• In the phase III ABC-06 study, patients were randomised to active symptom control alone or with FOLFOX (5-FU and oxaliplatin) chemotherapy.
• Several agents, such as pemigatinib and infigratinib (among others), are likely to have a similar efficacy, affording a progression-free survival in second and subsequent line therapy of 7–9 months.
• Ivosidenib has been shown to have progression-free survival advantage for patients with IDH1 mutations and is now adopted as standard of care in several countries, also after prior treatment with chemotherapy.